^
BIOMARKER:

CD38 positive

i
Other names: CD38, CD38 Molecule, ADP-Ribosyl Cyclase 1, ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1, 2'-Phospho-Cyclic-ADP-Ribose Transferase, 2'-Phospho-ADP-Ribosyl Cyclase, Cyclic ADP-Ribose Hydrolase 1, NAD(+) Nucleosidase, CD38 Antigen (P45), ADPRC 1, 2'-Phospho-ADP-Ribosyl Cyclase/2'-Phospho-Cyclic-ADP-Ribose Transferase, Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase, Cluster Of Differentiation 38, CADPr Hydrolase 1, CD38 Antigen, ADPRC1, T10
Entrez ID:
Related biomarkers:
5d
n-LPL/WM is rare, but patients usually present in advanced stages. It is easily confused with other small B-cell lymphomas with plasma cell differentiation, especially basing on morphologic features alone; thus the accurate diagnosis of n-LPL/WM requires a combination of clinical features, serum M protein, immunohistochemistry, bone marrow morphology,flow cytometry and MYD88 L265P mutation status etc. The prognosis of n-LPL/WM may be not very good, and further studies with more cases are needed.
Clinical • Journal • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD38 (CD38 Molecule) • SDC1 (Syndecan 1) • FCER2 (Fc Fragment Of IgE Receptor II)
|
MYD88 L265P • CD20 expression • CD38 positive • SDC1 positive
7d
Primary effusion lymphoma is an unusual type of lymphoma that classically involves fluid compartments, and only a subset develops adjacent or extracavitary solid tumors, with the gastrointestinal tract being the most frequently involved site. This unique presentation of PEL affecting the CNS, as exclusive leptomeningeal involvement in the absence of systemic disease or discrete mass lesions, has not been previously described to the best of our knowledge.
ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule) • SDC1 (Syndecan 1)
|
TNFRSF8 expression • CCND1 expression • CD38 positive • SDC1 positive
8d
Clinical • New P2 trial • Combination therapy • IO biomarker
|
CD38 (CD38 Molecule)
|
CD38 expression • CD38 positive
|
bortezomib • dexamethasone • Darzalex Faspro (daratumumab/hyaluronidase)
19d
In addition, multiparameter flow cytometry (FCM) revealed that CAR-T-38 cells eliminated CD38 positive blasts without off-target effects on monocytes and lymphocytes. Although this prospective study has a limited number of cases and a relatively short follow-up time, our preliminary data highlight the clinical utility and safety of CAR-T-38 cell therapy in treating relapsed AML post-allo-HSCT.
Journal • CAR T-Cell Therapy • IO biomarker
|
CD38 (CD38 Molecule)
|
CD38 positive
24d
Our data suggest that a high level of myosin 1C isoform A is a specific marker both for prostate cancer cells and prostate cancer cell lines. High expression of isoform A is associated with less activated (CD24/CD38 low) and more adhesive (CD29/CD54 high) surface phenotype compared to benign prostate tissue.
Journal • IO biomarker
|
CD38 (CD38 Molecule) • CD24 (CD24 Molecule) • ICAM1 (Intercellular adhesion molecule 1) • ITGB1 (Integrin Subunit Beta 1) • MME (Membrane metallo-endopeptidase)
|
CD38 positive
26d
Advanced or recurrent ECs identified as MSS are more sensitive to Pembrolizumab plus Lenvatinib, a receptor tyrosine kinase inhibitor (TKI), which slows the growth of endometrial cancer cells. Defining the specific immunological signature of EC can facilitate the rational design of targeted immunotherapy strategies.
PD(L)-1 Biomarker • IO biomarker
|
MSI (Microsatellite instability) • CD38 (CD38 Molecule) • CD40 (CD40 Molecule)
|
CD38 positive
|
Keytruda (pembrolizumab) • lenvatinib
26d
Advanced or recurrent ECs identified as MSS are more sensitive to Pembrolizumab plus Lenvatinib, a receptor tyrosine kinase inhibitor (TKI), which slows the growth of endometrial cancer cells. Defining the specific immunological signature of EC can facilitate the rational design of targeted immunotherapy strategies.
PD(L)-1 Biomarker • IO biomarker
|
MSI (Microsatellite instability) • CD38 (CD38 Molecule) • CD40 (CD40 Molecule)
|
CD38 positive
|
Keytruda (pembrolizumab) • lenvatinib
27d
Clinical • New P2 trial
|
CD38 (CD38 Molecule)
|
CD38 positive
|
bortezomib • Darzalex IV (daratumumab) • pomalidomide • dexamethasone • magrolimab (Hu5F9-G4)
1m
Conclusion Our study has shown that in MM with a complicated course, the identified CTCs subclone has a unique immunophenotypic protein expression profile, characterized by a less 'mature' phenotype and variable expression of adhesive molecules (CD138, CD56), which increases their ability to enter the peripheral blood from the bone marrow and cause extramedullary lesions. The data obtained are consistent with the literature data on the significant role of CD138-negative cells in MM, less 'mature' phenotype, and resistance to chemotherapy.
Clinical • Circulating Tumor Cells • IO biomarker
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • CD79B (CD79b Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD28 (CD28 Molecule) • CD33 (CD33 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1)
|
CD19 positive • CD38 positive • NCAM1 expression • SDC1 positive
1m
The release of the Granzyme A and B, TNF-alpha and CXCL-10 in the tumor micro-environment one week post-treatment was strongly and significantly increased by ISB 1342 but not by daratumumab and ISB 1342_13DU; this represents a correlate of anti-tumor immunity associated with ISB 1342 efficacy in vivo. Conclusion Hence the higher potency of ISB 1342 relative to daratumumab supports the ongoing clinical development in multiple myeloma patients.
IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • GZMA (Granzyme A)
|
CD38 expression • CD38 positive
|
Darzalex IV (daratumumab) • ISB 1342
1m
The Dara was given in combination with lenalidomide in 23.7% of patients, with bortezomib in 15.5%, with pomalidomide in 5.2% and with both lenalidomide and bortezomib in 3.1%. Conclusion Overall, our data seem to show that low expression of the checkpoint inhibitor CD200 and enrichment in inflammatory response genes expression is associated with good response to Dara. Further work is ongoing to understand the underlying mechanisms and to determine whether phenotypic or gene expression data could be used as predictive markers of response to Dara.
IO biomarker
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD27 • NCAM1 (Neural cell adhesion molecule 1) • CD200 (CD200 Molecule)
|
CD38 expression • CD20 expression • KIT expression • CD38 positive • NCAM1 expression • CD200 expression • CD27 expression
|
Revlimid (lenalidomide) • bortezomib • Darzalex IV (daratumumab) • pomalidomide
3ms
A strong correlation was identified between CD38 and PD-1 expression on CD8 T cells in tumors. CD8 T cells and their subtypes play a critical role in the prediction of prognosis.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
CD38 expression • PD-1 expression • CD8 expression • CD38 positive
3ms
P2, N=13, Completed, University of California, San Francisco | Phase classification: P=N/A --> P2 | N=10 --> 13
Phase classification • Enrollment change • IO biomarker
|
CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule)
|
CD38 positive • CD8 negative
|
Selzentry (maraviroc)
4ms
The survival of recurrent PBL after autologous hematopoietic stem cell transplantation is very poor. Salvage allogeneic hematopoietic stem cell transplantation may bring long-term survival opportunities for those patients. Further clinical studies are needed to explore the role of allogeneic hematopoietic stem cell transplantation in refractory and recurrent PBL.
Clinical • Journal
|
CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • SDC1 (Syndecan 1)
|
CD38 positive • SDC1 positive
|
bortezomib • epirubicin • dexamethasone
4ms
This method enhances the accuracy of detecting CD138-/ CD38+ malignant plasma cells by flow cytometry, and it serves as an important quality assurance that has substantial implications in further patient treatment.
IO biomarker
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1)
|
CD38 expression • CD38 positive • SDC1 positive
5ms
Daratumumab-containing regimen was consisted of daratumumab 400mg x 1, cytarabine 100mg/d x 3-5d, etoposide 100mg/d x 3-5d, and venetoclax 10mg bid x 14d. The prognosis of refractory/relapsed patients with hematological malignancies who relapsed after allo-HSCT is extremely poor, and effective therapeutic regimens are very limited. Our pilot study has shown that daratumumab-containing regimen is feasible and effective in half of CD38 positive hematological malignancies in children who relapsed after allo-HSCT. It seems that better response is found in the patients with T-LBL/L.
Clinical • IO biomarker
|
CD38 (CD38 Molecule)
|
CD38 expression • CD38 positive
|
Venclexta (venetoclax) • cytarabine • etoposide IV • Darzalex IV (daratumumab)
5ms
The patient has since successfully completed six planned cycles of VCD (Velcade, Cyclophosphamide and Dexamethasone) chemotherapy. Liver involvement by e-MM radiologically classically shows diffuse parenchymal involvement. We demonstrate a case with an unusual presentation of e-MM as hyper-enhancing well defined liver deposits and highlight the importance of its consideration in the differential diagnosis of focal liver lesions, in addition to hepatocellular carcinoma and hypervascular metastatic disease to ensure timely, appropriate clinical referral and commencement of appropriate therapy.
CD19 (CD19 Molecule) • SDC1 (Syndecan 1) • Cancer antigen 19-9
|
CD38 positive • SDC1 positive
|
bortezomib
5ms
Positive CD38 and ZAP-70 expressions were associated with a higher WWP1 expression (P=0.012 and 0.029, respectively) . An abnormal WWP1 mRNA expression was found in CLL patients with significant correlation with ZAP-70 and CD38 expressions, and WWP1 may become a new supplement of CLL prognostic markers.
Clinical • Journal • IO biomarker
|
TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus) • CD38 (CD38 Molecule)
|
TP53 mutation • CD38 expression • IGH mutation • CD38 positive
5ms
Majority of patients in this study received plerixafor for mobilization, which might abrogate the effect of daratumumab and lenalidomide on the graft and stem cell collection. Further studies to investigate impact of Dara on CD38 positive mobilized hematopoietic cells is warranted.
CD34 (CD34 molecule)
|
CD38 expression • CD34 positive • CD38 positive
|
Revlimid (lenalidomide) • Darzalex IV (daratumumab) • Mozobil (plerixafor)
5ms
Majority of patients in this study received plerixafor for mobilization, which might abrogate the effect of daratumumab and lenalidomide on the graft and stem cell collection. Further studies to investigate impact of Dara on CD38 positive mobilized hematopoietic cells is warranted.
CD34 (CD34 molecule)
|
CD38 expression • CD34 positive • CD38 positive
|
Revlimid (lenalidomide) • Darzalex IV (daratumumab) • Mozobil (plerixafor)
5ms
Majority of patients in this study received plerixafor for mobilization, which might abrogate the effect of daratumumab and lenalidomide on the graft and stem cell collection. Further studies to investigate impact of Dara on CD38 positive mobilized hematopoietic cells is warranted.
CD34 (CD34 molecule)
|
CD38 expression • CD34 positive • CD38 positive
|
Revlimid (lenalidomide) • Darzalex IV (daratumumab) • Mozobil (plerixafor)
5ms
Majority of patients in this study received plerixafor for mobilization, which might abrogate the effect of daratumumab and lenalidomide on the graft and stem cell collection. Further studies to investigate impact of Dara on CD38 positive mobilized hematopoietic cells is warranted.
CD34 (CD34 molecule)
|
CD38 expression • CD34 positive • CD38 positive
|
Revlimid (lenalidomide) • Darzalex IV (daratumumab) • Mozobil (plerixafor)
5ms
Majority of patients in this study received plerixafor for mobilization, which might abrogate the effect of daratumumab and lenalidomide on the graft and stem cell collection. Further studies to investigate impact of Dara on CD38 positive mobilized hematopoietic cells is warranted.
CD34 (CD34 molecule)
|
CD38 expression • CD34 positive • CD38 positive
|
Revlimid (lenalidomide) • Darzalex IV (daratumumab) • Mozobil (plerixafor)
6ms
Although PD-1 blockade with nivolumab did not affect MM cell viability or enhanced daratumumab-mediated lysis in short-term ex vivo experiments, nivolumab resulted in a mild but clear increase in T-cell numbers. Moreover, with a longer treatment duration, PD-1 blockade markedly improved anti-CD38 antibody-mediated cytotoxicity in vivo in murine CD38 tumor models. In conclusion, dual targeting of CD38 and PD-1 may represent a promising strategy for treating MM and other CD38-positive malignancies.
Preclinical • Journal • Combination therapy • PD(L)-1 Biomarker
|
CD38 (CD38 Molecule)
|
PD-L1 expression • CD38 expression • CD38 positive
|
Opdivo (nivolumab) • Darzalex IV (daratumumab)
6ms
Flow cytometric antibody binding assay is an objective way of evaluating the efficacy of DTT treatment for CD38 on RBCs. This approach allows the detection of a small number of cell surface antigens and will be useful for assessing the various chemical treatments to denature RBC antigens.
Journal
|
CD38 (CD38 Molecule)
|
CD38 positive
|
Darzalex IV (daratumumab) • Sarclisa (isatuximab-irfc)
7ms
Hydroxyurea initiated with leukocytosis control, but progressed with febrile neutropenia, pulmonary and urinary focus, without improvement despite the interventions administered, progressive deterioration until acute ventilatory failure and death... AML in elderly patients includes a comprehensive assessment of performance and comorbidities. Mutations are essential to determine the target therapy. In our case, the patient was unfit due to a history of progeroid syndrome.
Clinical • IO biomarker
|
FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • LMNA (Lamin A/C) • CD34 (CD34 molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD14 • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD33 (CD33 Molecule) • CD7 (CD7 Molecule)
|
FLT3-ITD mutation • CD34 positive • CD38 positive • CD33 positive
|
hydroxyurea
7ms
In particular, a dual-positive (CD138P-gpCD34) population is elevated in aggressive/unresponsive disease. Our test provides a personalised liquid biopsy with potential to address the unmet clinical need of monitoring MDR and treatment failure in myeloma.
Journal
|
CD34 (CD34 molecule) • SDC1 (Syndecan 1)
|
CD38 positive
7ms
In conclusion, we have shown that an increased percentage of M-MDSC cells producing IL-10 and TGF-β1 in CLL patients may be associated with the suppression of the immune response against CLL. It can be assumed that the increased percentage of M-MDSC with an intracellular expression of IL-10 and TGF-β1 may be used in the future as the factor defining the group of patients with shorter time to onset of treatment.
Journal
|
CD38 (CD38 Molecule) • CD14 • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • ITGAM (Integrin, alpha M)
|
Chr del(17)(p13.1) • CD38 positive • M-MDSCs
7ms
TAK-573 binds to a site on CD38 that is distinct from the binding sites of currently available therapeutic antibodies, and therefore does not compete for binding with daratumumab or isatuximab. TAK-573 is a clinically and pharmacologically active molecule that mediates IFNAR pathway modulation and leads to myeloma responses. Additional biomarker data is being collected to further refine the MOA, which will inform the recommended phase 2 dose, optimal schedule of administration, and rational development of TAK-573.
Clinical • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD38 (CD38 Molecule) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
|
CD38 positive
|
Darzalex IV (daratumumab) • Sarclisa (isatuximab-irfc) • modakafusp alfa (TAK-573)
7ms
A high proportion of 43% extra-medullary disease progression was observed in the current study which was not reported in the only similar study. Based on these data, Dara treatment for relapsing patients after allo-HCT creates no safety concerns and provides acceptable efficacy
Retrospective data
|
CD38 (CD38 Molecule)
|
CD38 positive
|
Darzalex IV (daratumumab)
7ms
In this study, we show that in a panel of 23 MM, AML and B-NHL cell lines HexaBody-CD38 induced CDC, with EC50 values on average 7-fold lower than those of the CD38-targeting mAb daratumumab, which is part of the standard of care for MM. This indicates that besides highly potent CDC, FcɣR-mediated effector mechanisms contribute to the preclinical activity of HexaBody-CD38 in hematological tumor models. These preclinical data support clinical investigation of HexaBody-CD38 in CD38 positive hematologic malignancies, including MM, AML, and B cell lymphomas.
IO biomarker
|
CD38 (CD38 Molecule)
|
CD38 expression • CD38 positive
|
Darzalex IV (daratumumab) • HexaBody-CD38
7ms
Blood 2019;925-925.), wherein 24 patients with R/R MM were treated with a combination therapy of venetoclax, daratumumab and dexamethasone, and the efficacy and safety of the therapy were evaluated. Thus, while the efficacy of the combination therapy of venetoclax and daratumumab has already been confirmed in a clinical trial, our data further shows the synergistic cytotoxic effect of venetoclax and daratumumab in vitro. Our in vitro analysis could, therefore, serve useful in the estimation of the effective dosage of each drug for the treatment of MM using clinical samples.
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD38 (CD38 Molecule)
|
BCL2 expression • CD38 positive
|
Venclexta (venetoclax) • Darzalex IV (daratumumab) • dexamethasone
7ms
The decitabine (DAC) + HAAG regimen was used to reduce tumor burden, followed by the fludarabine and cyclophosphamide (FC) regimen for lymphodepletion chemotherapy before CAR-T cell infusion...This study is the first to indicate that CAR-T-38 therapy is a promising effective and safe approach for patients with relapsed AML after allo-HSCT. (NCT04351022)
CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • CD38 (CD38 Molecule)
|
CD38 expression • CD38 positive
|
decitabine • cyclophosphamide intravenous • fludarabine IV
8ms
MTH1 highly expresses in CD138+ cells of some MM patients. MTH1 expression can increase in U266 cells treated by IL-6. The MTH1 inhibitor TH588 possesses proliferation-inhibitory effect and apoptosis-inducing effect on MM cell U266.
Journal
|
IL6 (Interleukin 6) • SDC1 (Syndecan 1)
|
CD38 positive • SDC1 positive
8ms
PUC generally occurs in elderly men with a poor prognosis. Awareness of the unique morphology and immunoprofile is important to avoid any misdiagnosis.
ER (Estrogen receptor) • CD163 (CD163 Molecule) • CALR (Calreticulin) • CDX-2 • SDC1 (Syndecan 1) • TTF-1 (Thyroid Transcription Factor-1) • GATA3 (GATA binding protein 3)
|
CD38 positive • SDC1 positive
8ms
The bone marrow biopsy subsequently performed was normal. Radiation therapy led to a decrease in IgM level and normal κ/λ ratio with complete regression of the mass.
IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD19 (CD19 Molecule) • PAX5 (Paired Box 5) • IRF4 (Interferon regulatory factor 4) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1)
|
CXCR4 mutation • CD38 positive • SDC1 positive
8ms
We recommend correlation of different techniques should be used for the proper diagnosis and characterization of myeloma. This unusual rare entity should be reported to clearly define its pathogenesis and prognostic implications.
Clinical
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • IRF4 (Interferon regulatory factor 4) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1)
|
CD38 positive • SDC1 positive
8ms
Unfortunately, residual disease was identified on recent positron emission tomography scan, requiring continuous close monitoring. Practicing pathologists should maintain a high level of awareness for plasmablastic lymphoma in immunocompromised patients, regardless of the site of involvement.
IO biomarker
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • PAX5 (Paired Box 5) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • ALK1 (Activin A Receptor Like Type 1) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1)
|
CD38 positive • SDC1 positive
8ms
Russell bodies are typically seen in chronic inflammation and less commonly in lymphoid or plasma cell neoplasms. This finding can support a diagnosis of PNLH.
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • SDC1 (Syndecan 1)
|
CD20 positive • CD38 positive • SDC1 positive
8ms
The patient was started on chemotherapy with Doxorubicin and Rituximab. Patients with HHV-8 MCD often manifest with constitutional symptoms, lymphadenopathy, hepatosplenomegaly and pulmonary manifestations. Our patient represents a common presentation of a rare disease during a global health crisis. We maintain the importance of resisting inherent biases when formulating a differential diagnosis.
CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • SDC1 (Syndecan 1)
|
CD20 positive • CD38 positive • SDC1 positive
|
Rituxan (rituximab) • doxorubicin hydrochloride
8ms
The clinical pharmacology profile of isatuximab was investigated by population pharmacokinetics modeling in 476 MM patients who received 1 to 20 mg/kg isatuximab either as single agent or in combination with pomalidomide-dexamethasone in 4 clinical trials. A typical 50% decrease in linear CL from initial treatment to steady state was predicted, and this decrease correlated with the best overall response rate and was slower for IgG MM patients. These findings suggest that the time-dependent effect of isatuximab is likely mediated by a combined factor of both disease state evolution and the perturbation of the FcRn-mediated recycling pathway.
Clinical • PK/PD data • Journal
|
CD38 (CD38 Molecule)
|
CD38 positive
|
pomalidomide • dexamethasone • Sarclisa (isatuximab-irfc)
9ms
Our studies establish DARA-IRDye800 as a promising contrast agent for preclinical evaluation of CD38 expression and for further investigating myeloma engraftment and kinetics in relation to anti-CD38 therapies.
Preclinical • Journal
|
CD38 (CD38 Molecule)
|
CD38 expression • CD38 positive
|
Darzalex IV (daratumumab)
9ms
he was treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD chemotherapy regimen)...He was admitted and treated with Cyclophosphamide, vincristine, doxorubicin, dexamethasone, rituximab (Hyper-Cvad chemotherapy regimen)... HGBL after therapy of HL is an extremely rare condition. HGBL can occur primarily and incidentally or may be secondary to chemotherapeutic agents previously used. Although first hematologic malignancy was totally cured, our patients monitoring must continue regularly.
Clinical
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
|
CD20 positive • BCL2 rearrangement • BCL6 rearrangement • CD38 positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • vincristine • dacarbazine • cyclophosphamide intravenous • dexamethasone • bleomycin • vinblastine
9ms
MYC amplification led to high expression of MYC and rapid disease progression, indicating its clinical significance in the pathogenesis of MM/PCL. MYC amplification on dmin may be a very rare genetic event closely associated with the progression to PCL and coexistence of IGH/CCND1 fusions.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
MYC amplification • MYC expression • MYC rearrangement • CD38 positive
9ms
The scalp lesions resolved following chemotherapy with ixazomib, lenalidomide and dexamethasone, but three new nodules reappeared on the scalp 6 months later...She has since switched to a new chemotherapy regime on Velcade®, dexamethasone and daratumumab...This may be due to a diffuse invasion of plasma cells indicating widespread systemic MM involvement. Cutaneous manifestations of MM may therefore become a useful prognostic tool in the future.
Clinical
|
SDC1 (Syndecan 1)
|
CD38 positive • SDC1 positive
|
Revlimid (lenalidomide) • bortezomib • Ninlaro (ixazomib) • Darzalex IV (daratumumab) • dexamethasone
10ms
Clinical • Enrollment closed • Enrollment change
|
CD8 (cluster of differentiation 8)
|
CD38 positive
|
Blenrep (belantamab mafodotin)
10ms
The patient was treated with six courses of lymphoma chemotherapy and attained complete remission without any symptoms associated with amyloidosis. Further case analyses are needed to clarify the clinicopathological findings and to establish therapeutic strategy of AL amyloidosis associated with FL and FL with plasmacytic differentiation.
Clinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2)
|
CD38 positive
11ms
We conclude that T-ALL has a high level of CD38 expression which is not associated with prognosis. Very high MRD level (> 10%) is related to the worse survival, however, FCM based MRD detection does not convey a significant prognostic value.
Clinical • Journal
|
CD38 (CD38 Molecule)
|
CD38 expression • CD38 positive
11ms
Further association studies are needed to verify prognostic relevance of the CCR1/CCR2 expression on leukemic cells in CLL patients at diagnosis. We suggest that CCR1/CCR2 signaling pathways could represent attractive targets for development of CLL anti-progression therapeutics.
Clinical • Journal
|
CD38 (CD38 Molecule)
|
CD38 expression • CD38 positive
11ms
The 9 pts who received lenalidomide/thalidomide-based regimens achieved CR with only 2 reported relapses...Bortezomib and lenalidomide are promising add-on agents. Legal entity responsible for the study: The authors. Funding: Has not received any funding.
Clinical • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • SDC1 (Syndecan 1)
|
MYC rearrangement • CD38 positive • SDC1 positive
|
Revlimid (lenalidomide) • bortezomib • thalidomide
over1year
Clinical • Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8)
|
CD38 positive
|
Blenrep (belantamab mafodotin)
over1year
P1, N=12, Recruiting, GlaxoSmithKline, Trial completion date: Mar 2021 --> Jul 2021 | Trial primary completion date: Mar 2021 --> Jul 2021
Clinical • Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8)
|
CD38 positive
|
Blenrep (belantamab mafodotin)
over1year
Clinical • Enrollment open
|
CD8 (cluster of differentiation 8)
|
CD38 positive
|
Blenrep (belantamab mafodotin)
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our